Galectin Therapeutics Inc.

NASDAQ:GALT

Biotechnology

Healthcare
$2.98 +1.62%

+$0.05 today

Market cap
$196.25M
Beta
0.49
P/E (TTM)
-7.1
EPS (TTM)
-$0.40
52W Low $1.85High $7.13

Volume 0.23M

Average 0.32M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$23.88M

FY 2025 · Annual

Investing Cash Flow

$0.00

FY 2025 · Annual

Financing Cash Flow

$26.48M

FY 2025 · Annual

-15.2% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(30.53M)(38.78M)(41.07M)(47.05M)(30.84M)
Depreciation & Amortization41K32K33K37K53K
Deferred Income Tax00000
Stock-Based Compensation2.08M2.87M2.26M2.45M1.66M
Change in Working Capital3.75M4.97M4.68M2.28M609K
Accounts Receivables00000
Inventory00000
Accounts Payables3.69M4.24M2.67M(2.07M)(6.04M)
Other Working Capital65K724K2.01M4.36M6.65M
Other Non-Cash Items351K(147K)1.13M512K4.64M
Operating Cash Flow(24.31M)(31.06M)(32.97M)(41.77M)(23.88M)
Capital Expenditures00000
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow00000
Debt Repayment30M10M30M30M21M
Common Stock Issued6.81M001.23M5.48M
Common Stock Repurchased00000
Dividends Paid(171K)00(91K)0
Other Financing Activities171K010.03M91K0
Financing Cash Flow36.81M10M40.03M31.23M26.48M
Effect of Forex Changes00000
Net Change in Cash12.51M(21.06M)7.07M(10.54M)2.6M
Free Cash Flow(24.31M)(31.06M)(32.97M)(41.77M)(23.88M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$30.8M
+ D&A$53.0K
+ Stock-Based Comp$1.7M
+ Deferred Tax$0
+ Working Capital$609.0K
+ Other Non-Cash$4.6M
= Operating Cash Flow-$23.9M
- Capex$0
= Free Cash Flow-$23.9M

Analysis

FY2025 free cash flow is -$23.9M. FCF conversion is 77.4% of net income. Operating cash flow was -$23.9M, with capex of $0. The largest bridge item is Other Non-Cash at $4.6M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
ARSARS filingOct 13, 2026
DEF 14ADEF 14A filingOct 13, 2026
DEFA14ADEFA14A filingOct 13, 2026
PRE 14APRE 14A filingOct 2, 2026
10-QQuarterly reportAug 14, 2026

Does GALT generate free cash flow?

Galectin Therapeutics Inc. (GALT) generated -$23.88M of free cash flow in fiscal 2025.

How much operating cash flow does GALT produce?

Operating cash flow was -$23.88M, before capital expenditures of $0.00.